| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payments made for additions to intangible assets | 0 | 0 |
| Net cash used in investing activities | -24,960 | -22,733 |
| Proceeds from issuance of common stock pursuant to equity plans | 31,143 | 15,047 |
| Net cash provided by financing activities | 31,143 | 15,047 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 3,630 | 3,281 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 59,573 | 5,674 |
| Cash and cash equivalents at beginning of period | 222,928 | - |
| Cash and cash equivalents at end of period | 282,501 | - |
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)